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Abstract
Aim of the study: To examine if differences in benzodiazepine use
between two urban regions in Belgium could be explained by socio-
demographic and health related factors.
Method: Two samples of 2400 respondents from all members of the
Christian and socialist health insurance agencies of Aalst and Liège,
aged at least 45 years. Respondents were interviewed at home on
sociodemographic and health related issues and filled out health related
questionnaires. They also showed all the drugs used at the moment 
of the interview. Univariate and multivariate analyses were done to
determine the predictors of benzodiazepine use. 
Main findings: The prevalence of benzodiazepine use was signifi-
cantly higher in Liège (27.2%) than in Aalst (19.6%). Marked differences
were also found between Aalst and Liège on most sociodemographic
and health-related variables. A logistic regression analysis including
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region, sociodemographic characteristics and health behaviours/attitudes
as independent predictors of benzodiazepine use still resulted in a
significant influence of the factor ‘region’. However, this influence turned
out to be insignificant when the respondent’s morbidity was taken into
account.
Conclusions: Differences in benzodiazepine use between Liège and
Aalst are partly explained by differences in self-reported morbidity.
Objective morbidity data and information on prescribers might give more
insight in such regional differences. 
Key words: benzodiazepines, survey, community, drug utilization
Introduction
Regional differences in the consumption and sales of sedative and
anti-anxiety drugs are found in several studies. A cross-national survey
in 10 European countries and the United States (1) showed that Belgium
had the highest prevalence of sedative and anti-anxiety drug use: 17.6%
of all adults used these drugs at least once in the past year. Within
Belgium, regional differences exist in the use of benzodiazepines as the
most frequently prescribed anti-anxiety and sedative drugs. A study in
members of the Belgian socialist health insurance agency found that
20.2% of inhabitants from Wallonia (the southern part of Belgium) took
tranquillizers daily, compared to 15.1% of inhabitants from Flanders 
(the northern part of Belgium) (2). The total consumption (daily and inter-
mittent) was also higher in Wallonia than in Flanders, but this difference
was not significant. Since the respondents in this study were members
of a particular health insurance agency, they were not representative
for the total population. Regional differences in anti-anxiety and seda-
tive drug sales also exist in other European countries (3-5). Some 
studies examined which factors could possibly explain such regional 
differences. Williams et al. (1986) found that expenditures in other health
services and the degree of urbanisation were independent positive
predictors of the sales of tranquillizers and hypnotics (3). However, these
factors did not explain the higher sales in the North/Centre of Italy
compared to the South. Bjorndal and Fugelli (1989) examined if the
higher consumption of tranquillizers and hypnotics in the North of Norway
compared to the South could be explained by variations in general
practitioners’ threshold of prescribing (4). On the basis of written 
simulations of patients, no difference in threshold of prescribing was
found between the general practitioners in the two regions, although the
research method (case simulation) is subject to criticism due to 
insufficient validity.
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This article describes the results of a secondary analysis on data
gathered in a study about the effect of continuity of care with the general
practitioner in the use of health care (6). The aim of this secondary
analysis was twofold. First, the two regions of Belgium involved in the
study were compared for the prevalence of benzodiazepine use, and its
relation to the consumption of other drugs. Second, it was examined
whether regional variation in the use of benzodiazepines could be
explained by differences between the inhabitants of both regions in
sociodemographic and health related factors. The available data had
two major advantages. As they represented actual drug consumption,
they were more informative than data about drug sales. Moreover, since
they were retrieved from individual patients, it was possible to control for
other factors at the patient level. 
Methods
Sample selection
A sample of 4800 inhabitants from two Belgian regions – Aalst and
Liège – was obtained from all members of the Christian and the 
socialist health insurance agencies aged 45 years or older (n= 245,460).
A restriction to two regions was necessary for reasons of feasibility. Aalst
and Liège were chosen because they were comparable for their avail-
able health services, and both regions disposed of a computerized indi-
vidual registration system for medical service utilisation. A rectangular
structure was used for sample selection, with stratification by region,
insurance agency, gender and age. An advantage of this sampling
structure was that it allowed for comparisons between corresponding
subgroups. The sample was drawn at random from the (anonymous)
member lists by the research team. For each case, three other cases
within the same age range, sex, insurance agency and area code
were provided beforehand, such that refusals could be replaced. 
A total of 7461 people were contacted to reach the final sample of 
4800 respondents. 
Materials
Respondents were interviewed at home between April and
September 1995. A standardised interview was used to gather informa-
tion on sociodemographic characteristics (civil state, form of cohabitation,
education level, employment status, income, living area, housing) and
health related behaviours (smoking, excessive alcohol use [defined as
consumption of 6 or more alcoholic beverages during one day at least
once in the preceding six months, exercising sports]). Health locus of
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control (HLC) was measured by a 9-item scale (7) composed by three
dimensions (3 items per scale): internal HLC; external HLC; chance
HLC. To reduce the number of missing values, the dimensions were
scored positive (value 1) if the respondent (strongly) agreed with at least
two of three items, and negative (value 0) if the respondent (strongly)
disagreed with at least two of three items. In all other cases, a dimen-
sion score was not computed. Health functioning was measured by a
Dutch version of the MOS-SF36 (8), which resulted in nine dimension
scores: general health, physical functioning, social functioning, role
limitations due to physical problems, role limitations due to emotional
problems, mental health, vitality, pain and health change. The dimension
‘health change’ was not used in the analysis, since the great majority
of respondents reported no change over the last year. To facilitate 
interpretation of results and to categorize the scores according to inter-
national standards, the MOS-SF36 scales were recoded into four cate-
gories according to their quartile scores. For ‘social functioning’ and
both ‘role limitations’ scales, the lowest quartile was compared to all
other scores, because the distribution of the raw scores did not allow for
categorisation into four quartiles. Information on morbidity was gathered
in a standardised way. First, respondents were asked about all chronic
health problems they experienced since at least six months. Afterwards
the interviewer read aloud a list of chronic disorders to check for 
completeness of the answer. Some disorders were possibly not
registered if the respondent underestimated their seriousness. On the
other hand, disorders might be over-represented if respondents used a
common diagnostic name when they did not know the real diagnosis. All
disorders were coded with the International Classification of Primary
Care (9). If several symptoms, complaints or disorders from the same
class were mentioned, only one was withheld for the analysis, to prevent
overestimation of symptoms representing the same pathology. To gather
information on medication use, the following question was asked: ‘Can
you show me the medications you use at the moment (homeopathic
products, vitamins, minerals, contraceptives, hormonal treatment
included)? Are they prescribed or not?’ The interviewer wrote down the
name, form and dose of each package shown. All products were
classified according to the ‘Commentated Drug repertory’ of the Belgian
Centre for Pharmacotherapeutic Information (10). The following infor-
mation on benzodiazepines was collected: actual use, number and
dose unit of different brands used. No information was available on the
duration or frequency of benzodiazepine use, neither on the daily dose
taken.
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Analysis
SPSS was used for data analysis (11). First, drug use was analysed
per region and then compared between users and non-users in each
region. Second, univariate relationships between sociodemographic and
health characteristics on the one hand, and the variables ‘region’ and
‘use of benzodiazepines’ on the other hand were examined. Pearson 
chi square statistics or odds ratios were used for categorical variables; 
t-tests or Mann Whitney U-tests were used for the comparison of 
variables of at least ordinal level.
Third, a logistic regression analysis (method enter) was executed to
determine significant independent predictors of the use of benzo-
diazepines. All variables with a p-value on the univariate test < 0.05 
for the comparison between users of benzodiazepines and non-users
were included in the logistic regression analysis.
Results
Use of benzodiazepines and other medications for the central nervous
system
Almost one in four respondents (23.4%) used one or more benzo-
diazepines at the time of the survey. In most cases (96.6%), the intake
of only one brand was reported. As can be seen in table 1, the preva-
lence of benzodiazepine use was significantly higher in Liège (27.2%)
than in Aalst (19.6%, p<0.001). Similarly, a significantly higher use was
observed in Liège for the following central nervous system drugs: non-
benzodiazepine hypnosedatives and anxiolytics, antidepressants, neu-
roleptics, antihistaminics, anti-epileptics and medications used for
migraine (table 1 first column). The separate columns for Aalst and Liège
in table 1 also show that use of other drugs for the central nervous
system was reported more often in the group of benzodiazepine users
compared to non-users for both regions. A combination of benzo-
diazepines with antidepressants was often reported in benzodiazepine
users, with a prevalence of 13% in Aalst and 17% in Liège. 
Use of medications for other systems
Significantly more use was reported in Liège compared to Aalst for
all medication groups, except for respiratory system drugs (data not
shown). 
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Univariate comparisons between regions
All available sociodemographic and health related variables were
compared between Aalst and Liège with a statistical test, except for the
variables used in the rectangular sample selection (age, gender and
health insurance).
The left columns of table 2a show marked differences between both
regions on almost all variables on which information was gathered in
the survey. That is, respondents in Liège differed from respondents in
Aalst in the following ways: a lower prevalence of marriage and employ-
ment, more people living alone, more people with high educational lev-
els, more people living in an apartment/studio/room, more people from
an urban area, more people reporting an insufficient income. For health
related behaviours and attitudes, the following differences were found in
Liège compared to Aalst: more people smoked, more people exercised
sports, more people had a positive score on each of the locus of con-
trol dimensions (internal, external and chance). The only variable for
which inhabitants from Liège were comparable with inhabitants from
Aalst was the prevalence of excessive alcohol use: in both regions the
prevalence was somewhat higher than one to five. Table 2b (left
columns) shows significantly worse levels of functioning in Liège than in
Table 1: Use of other medication for the central nervous system: number of users in
Aalst and Liège and comparison of benzodiazepine users with non-users per region.
Medication Aalst Liège Aalst (n=2400) Liège (n=2400)
(n=2400) (n=2400)
n (%) n (%)
benzodiazepines 469 653 BZ users non-users p BZ users non-users p
(19.6) (27.2) n (%) n (%) n (%) n (%)
other hypnotics, 44 (1.8) 25 (1.0) 16 (3.4) 28 (1.5) 0.005 27 (4.1) 39 (2.2) 0.011
sedatives, anxiolytics
antidepressants 105 (4.4) 177 (7.4) 59 (12.6) 46 (2.4) <0.001 110 (16.8) 67 (3.8) <0.001
neuroleptics 55 (2.3) 118 (4.9) 29 (6.2) 26 (1.3) <0.001 71 (10.9) 47 (2.7) <0.001
antihistaminics 67 (2.8) 102 (4.3) 23 (4.9) 44 (2.3) 0.002 42 (6.4) 60 (3.4) 0.001
parkinson 26 (1.1) 39 (1.6) 10 (2.1) 16 (0.8) 0.015 19 (2.9) 20 (1.1) 0.002
anti-epileptics 18 (0.8) 33 (1.4) 3 (0.6) 15 (0.8) 0.755 13 (2.0) 50 (1.1) 0.001
spasticity 16 (0.7) 25 (1.0) 3 (0.6) 13 (0.7) 0.934 13 (2.0) 12 (0.7) 0.005
migrain 3 (0.1) 12 (0.5) 1 (0.2) 2 (0.1) 0.548 7 (1.1) 5 (0.3) 0.015
central stimulants 5 (0.2) 8 (0.3) 2 (0.4) 3 (0.2) 0.249 3 (0.5) 5 (0.3) 0.512
cholinesterase inhib. 4 (0.2) 0 (0.0) 1 (0.2) 3 (0.2) 0.784 0 (0.0) 0 (0.0) –
Legend: n= number; p= p-value statistical test
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Aalst on most dimensions of the MOS-SF36, except for role functioning
due to physical problems. However, significantly more people in Liège
than in Aalst reported a good level of general functioning, which seems
to contradict the results on the MOS-subscales and self-reported 
disorders. Indeed, when respondents were asked about their health
disorders, inhabitants from Liège reported more physical and central
nervous system disorders than inhabitants from Aalst. No significant
difference was found between Aalst and Liège for self-reported mental
disorders. On the contrary, a highly significant discrepancy existed for
self-reported mental functioning on the MOS-SF36 scale in the advan-
tage of Aalst.
Table 2a: Sociodemographic variables and health related behaviours/attitudes: compari-
son between regions and between users and non-users for the total sample (n=4800)
Variable REGION USE OF BENZODIAZEPINES
Aalst (n=2400) Liège (n=2400) Users Non-users
n (%) n (%) n (%) n (%)
Gender (OR ; 95% CI)* OR=0.52 (0.45-0.59)
male 1197 (50) 1200 (50) 422 (37.6) 1975 (53.8)
female 1199 (50) 1200 (50) 700 (62.4) 1699 (46.2)
Age (years)* t=0.27 (p=0.78) t=10.42 (p<0.001)
mean 68.4(SD 11.45) mean 68.4 (SD 11.69) mean 71.5 (SD 10.4) mean 67.5 (SD 11.74)
Insurance institute
(OR; 95% CI)* OR= 0.79 (0.69-0.90)
CM 1197 (49.9) 1200 (50) 509 (45.4) 1888 (51.4)
SM 1199 (50) 1200 (50) 613 (54.6) 1786 (48.6)
Civil state p<0.0001 p<0.0001
married 1633 (68.4) 1302 (54.4) 566 (50.4) 2369 (64.5)
unmarried 111 (4.6) 187 (7.8) 66 (5.9) 232 (6.3)
divorced 79 (3.3) 265 (11.1) 92 (8.2) 252 (6.9)
widowed 566 (23.7) 636 (26.6) 392 (34.9) 810 (22.0)
Education level p<0.0001 p<0.0001
no certificate 608 (25.5) 406 (17.1) 256 (23.1) 758 (20.8)
primary education 683 (28.7) 602 (25.3) 345 (31.1) 940 (25.8)
lower secondary 619 (26.0) 691 (29.0) 299 (26.9) 1011 (27.7)
higher secondary 312 (13.1) 346 (14.5) 117 (10.5) 541 (14.8)
higher education 158 (6.6) 335 (14.1) 93 (8.4) 400 (11.0)
Employment status p=0.003 p<0.0001
Employed 357 (15.1) 284 (12.0) 42 (3.8) 599 (16.5)
unemployed/work unable 160 (6.8) 202 (8.5) 92 (8.3) 270 (7.4)
retired 1680 (70.9) 1699 (71.5) 883 (79.7) 2496 (68.6)
housewife(man) 173 (7.3) 190 (8.0) 91 (8.2) 272 (7.5)
Housing situation
(OR; 95% CI) OR=6.78 (5.66-8.11) OR= 0.61 (0.52-0.71)
house 2164 (92.9) 1542 (65.9) 796 (72.8) 2910 (81.4)
apartment/studio/room 165 (7.1) 797 (34.1) 298 (27.2) 664 (18.6)
234 Habraken H, De Maeseneer J, De Prins L, Gosset C
Univariate comparisons between users of benzodiazepines and 
non-users
The right columns of table 2a show the associations between use of
benzodiazepines and the other variables examined. In respondents who
used benzodiazepines, more people were female, older, widowed, less
educated, retired, living alone, had an insufficient income, lived in an
Variable REGION USE OF BENZODIAZEPINES
Aalst (n=2400) Liège (n=2400) Users Non-users
n (%) n (%) n (%) n (%)
Income (OR; 95% CI) OR= 2.16 (1.85-2.53) OR= 0.64 (0.54-0.76)
sufficient 2087 (87.9) 1844 (77.2) 579 (69.6) 3070 (78.1)
insufficient 286 (12.1) 546 (22.8) 253 (30.4) 861 (21.9)
Living Area 
(OR; 95% CI) OR=5.69 (4.73-6.86) OR= 0.75 (0.63-0.88)
rural 2193 (93.4) 1681 (71.4) 870 (79.0) 3004 (83.5)
urban 154 (6.6) 672 (28.6) 231 (21.0) 595 (16.5)
Form of cohabitation p<0.0001 p<0.0001
living alone 543 (22.7) 785 (32.9) 418 (37.3) 910 (24.9)
with partner only 1220 (51.0) 957 (40.1) 464 (41.4) 1713 (46.8)
with partner and children 400 (16.7) 397 (16.6) 112 (10.0) 685 (18.7)
other 230 (9.6) 248 (10.4) 126 (11.3) 352 (9.6)
Excessive alcohol use
(OR; 95% CI) OR=1.06 (0.92-1.21) OR= 0.55 (0.46-0.66)
yes 528 (22.5) 509 (21.6) 164 (14.9) 873 (24.3)
no 1817 (77.5) 1848 (78.4) 938 (85.1) 2727 (75.8)
Smoking
(OR; 95% CI) OR=0.60 (0.52-0.69) OR= 0.78 (0.66-0.92)
yes 428 (17.9) 642 (26.8) 214 (19.1) 856 (23.4)
no 1960 (82.1) 1754 (73.2) 905 (80.9) 2809 (76.6)
Exercising sports
(OR; 95% CI) OR=0.81 (0.71-0.91) OR= 0.51 (0.44-0.60)
yes 684 (28.7) 792 (33.2) 232 (20.8) 1244 (34.0)
no 1703 (71.3) 1590 (66.8) 881 (79.2) 2412 (66.0)
Health Locus of Control 
Internal (OR; 95% CI) OR=0.48 (0.41-0.55) OR= 0.73 (0.63-0.86)
yes 1552 (69.9) 1937 (83.0) 766 (72.2) 2723 (78.0)
no 667 (30.1) 396 (17.0) 295 (27.8) 768 (22.0)
Health Locus of control 
External (OR; 95% CI) OR=0.61 (0.54-0.68) OR= 1.92 (1.66-2.22)
yes 1059 (47.8) 1409 (60.1) 699 (66.2) 1769 (50.5)
no 1158 (52.2) 934 (39.9) 357 (33.8) 1735 (49.5)
Health Locus of Control 
Chance (OR; 95% CI) OR=0.60 (0.53-0.67) OR= 1.09 (0.94-1.26)
yes 974 (47.0) 1326(59.8) 543 (55.2) 1757 (53.1)
no 1098 (53.0) 893 (40.2) 440 (44.8) 1551 (46.9)
Legend: * statistical test only for the comparison between users and non-users, because the sample was stratified on this
variable; OR= odds ratio (Aalst versus Liège or users versus non-users); CI= confidence interval; n= number; p= p-value
of the statistical test
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apartment, were from an urban area, did not smoke, showed no exces-
sive alcohol use, did not exercise sports, or were member of the socialist
health insurance. Benzodiazepine users also had a higher chance to
have an external health locus of control, and a lower chance of an inter-
nal health locus of control. No association was found between benzodi-
azepine consumption and a chance oriented health locus of control. 
As can be noted from table 2b (right columns), users of benzodi-
azepines reported a lower level of functioning on all MOS-SF36 health
dimensions. Also, the prevalence of benzodiazepine use increased if
physical, mental or central nervous system disorders were present. 
Table 2b: Health functioning and morbidity: comparison between regions 
and between benzodiazepine users and non-users for the total sample (n=4800).
REGION USE OF BENZODIAZEPINES
Variable Aalst Liège Users Non-users
SF36 general health p<0.0001 p<0.0001
P 1-25 719 (30.6) 744 (31.4) 548 (49.5) 915 (25.4)
P 26-50 592 (25.2) 481 (20.3) 226 (20.4) 874 (23.5)
P 51-75 680 (29.0) 639 (27.0) 239 (21.6) 1080 (30.0)
P 76-100 355 (15.1) 503 (21.3) 95 (8.6) 763 (21.2)
SF36 physical functioning p=0.0388 p<0.0001
P 1-25 590 (24.9) 593 (25.1) 431 (39.1) 752 (20.7)
P 26-50 643 (27.2) 708 (30.0) 372 (33.8) 979 (27.0)
P 51-75 528 (22.3) 533 (22.6) 198 (18.0) 863 (23.8)
P 76-100 606 (25.6) 529 (22.4) 101 (9.2) 1034 (28.5)
SF36 social functioning p<0.0001 p<0.0001
P 1-25 608 (25.4) 795 (33.2) 512 (45.7) 891 (24.3)
P 26-100 1783 (74.6) 1596 (66.8) 609 (54.4) 2770 (75.7)
SF36 mental health p<0.0001 p<0.0001
P 1-25 379 (16.1) 827 (34.9) 508 (45.7) 698 (19.3)
P 26-50 601 (25.5) 736 (31.0) 334 (30.1) 1003 (27.7)
P 51-75 675 (28.6) 487 (20.5) 160 (14.4) 1002 (27.7)
P 76-100 705 (29.9) 323 (13.6) 109 (9.8) 919 (25.4)
SF36 role-physical p=0.297 p<0.0001
P 1-25 709 (30.4) 687 (29.0) 491 (44.7) 905 (25.1)
P 26-100 1626 (69.6) 1684 (71.0) 607 (55.3) 2703 (74.9)
SF36 role-emotional p<0.0001
P 1-25 574 (24.7) 794 (33.5) 483 (44.2) 885 (24.6)
P 26-100 1750 (75.3) 1573 (66.5) 609 (55.8) 2714 (75.4)
SF36 pain p<0.0001 p<0.0001
P 1-25 591 (24.7) 667 (36.2) 527 (47.1) 931 (25.4)
P 26-50 530 (22.1) 533 (22.2) 251 (22.4) 812 (22.1)
P 51-75 572 (23.9) 507 (21.2) 192 (17.1) 887 (24.2)
P 76-100 701 (29.3) 490 (20.4) 150 (13.4) 1041 (28.4)
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Logistic regression analysis
To see which variables were independently related to the use of ben-
zodiazepines, they were considered in a logistic regression analysis.
First, the variable ‘region’, all other sociodemographic variables, and
variables indicating health behaviours/attitudes were included in the
analysis. The effect of region was still significant after controlling for
these variables (table 3, left column). Next, the MOS-SF36 dimensions
and self-reported physical, mental and central nervous system disorders
were included (table 3, right column). The odds of using benzodiazepines
compared to the odds of not using benzodiazepines significantly
increased with being female; being older; not being employed; having
an external health locus of control orientation; reporting mental disorders
or physical disorders. On the other hand, the odds decreased with report-
ing better mental health and reporting more vitality. The association
between region and use of benzodiazepines was no longer significant
when morbidity variables were taken into account (table 3, right column).
REGION USE OF BENZODIAZEPINES
Variable Aalst Liège Users Non-users
SF36 vitality p<0.0001 p<0.0001
P 1-25 409 (17.3) 906 (38.1) 539 (48.5) 776 (21.4)
P 26-50 527 (22.3) 838 (35.3) 304 (27.3) 1061 (29.3)
P 51-75 566 (24.0) 401 (16.9) 169 (15.2) 798 (22.0)
P 76-100 860 (36.4) 232 (9.8) 100 (9.0) 992 (27.4)
Disorders physical
OR (95% CI) OR=0.58 (0.50-0.66) OR=3.11 (2.55-3.80)
one or more 1699 (70.9) 1941 (80.9) 997 (88.9) 2643 (71.9)
none 697 (29.1) 459 (19.1) 125 (11.1) 1031 (28.1)
Disorders mental
OR (95% CI) OR=0.88 (0.67-1.14) OR= 6.49 (4.93-8.53)
one or more 111 (4.6) 126 (5.3) 151 (13.5) 86 (2.3)
none 2285 (95.4) 2274 (94.8) 971 (86.5) 3588 (97.7)
Disorders central nervous system
OR (95% CI) OR=0.78 (0.64-0.94) OR=1.93 (1.57-2.36)
one or more 204 (8.5) 257 (10.7) 163 (14.5) 298 (8.1)
none 2192 (91.5) 2143 (89.3) 959 (85.5) 3376 (91.9)
Legend: OR=odds ratio; CI=confidence interval, P=percentile, p=p-value statistical test
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Table 3: Results of logistic regression analysis (method enter) with use 
of benzodiazepines as the dependent variable: odds ratios and 95% confidence interval
of variables included in the model without morbidity variables and variables included 
in the model with morbidity variables.
Model without morbidity Model with morbidity 
variables variables
Variable OR 95% CI OR 95% CI
living in Liège (compared to Aalst) 1.45 1.22-1.72 1.00 0.81-1.24
female (compared to male) 1.64 1.37-1.95 1.48 1.22-1.80
age (increase of 1 year) 1.01 1.00-1.02 1.02 1.01-1.03
external HLC (compared to no) 1.01 1.00-1.02 1.02 1.01-1.03
not employed (compared to employed) 2.94 1.99-4.36 2.23 0.30-0.68
living at an appartment/studio/room 1.20 0.95-1.53 1.30 1.00-1.70
(compared to living at a house)
civil state (compared to ‘married’)
unmarried 0.94 0.64-1.37 0.97 0.64-1.46
legal divorce 1.01 0.69-1.49 0.90 0.59-1.38
actual divorce 1.42 0.82-2.44 1.05 0.56-1.95
widowed 1.12 0.85-1.47 1.01 0.75-1.36
education level (compared to none)
primary education 1.17 1.14-1.20 1.25 0.98-1.58
lower secondary education 1.13 0.90-1.43 1.22 0.95-1.56
higher secondary education 1.08 0.80-1.44 1.14 0.83-1.56
higher education 1.44 1.04-2.00 1.47 1.03-2.11
insufficient income (compared to sufficient) 1.36 1.12-1.66 0.88 0.70-1.10
living in an urban area (compared to rural) 0.85 0.66-1.09 0.78 0.59-1.03
not living alone (compared to living alone) 0.86 0.66-1.11 0.83 0.90-1.59
insurance at SM (compared to CM) 1.26 1.08-1.48 1.16 0.97-1.39
excessive alcohol use (compared to no) 0.99 0.80-1.24 1.06 0.84-1.35
smoking (compared to no) 0.93 0.76-1.14 0.92 0.74-1.15
exercising sport (compared to no) 1.20 1.09-1.32 1.09 0.98-1.21
internal HLC (compared to no) 0.77 0.65-0.92 1.01 0.82-1.23
MOS-SF36: 
general health (compared to P0-24)
P 25-49 0.74 0.58-0.95
P 50-74 0.96 0.73-1.25
P 75-100 0.81 0.57-1.16
physical functioning (compared to P0-24)
P 25-49 1.05 0.83-1.32
P 50-74 1.09 0.80-1.48
P 75-100 0.87 0.59-1.27
Pain (compared to P0-24)
P 25-49 0.96 0.75-1.22
P 50-74 1.03 0.78-1.23
P 75-100 0.90 0.66-1.23
social functioning P25-100 (compared to P0-24) 0.99 0.79-1.24
role physical P25-100 (compared to P0-24) 1.12 0.89-1.40
role emotional P25-100 (compared to P0-24) 0.81 0.66-1.01
mental health (compared to P0-24)
P 25-49 0.72 0.58-0.91
P 50-74 0.46 0.34-0.61
P 75-100 0.41 0.29-0.57
Vitality (compared to P0-24)
P 25-49 0.65 0.51-0.82
P 50-74 0.81 0.59-1.11
P 75-100 0.53 0.37-0.78
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Discussion
The study findings concerning differences between users of benzodi-
azepines and non-users on sociodemographic and health characteristics
were comparable to the results from other studies (12-20). The fact that
gender was still a significant predictor of benzodiazepine use after con-
trolling for other variables confirmed the results of two other studies (13)
(20), but was not in line with the results of a population survey in the
Belgian province of East-Flanders (21). This might be due to discrepan-
cies between both samples on other characteristics (e.g. age distribution)
or between the study definitions of the dependent variable (actual use 
versus long-term daily use). Since the data of the current study were not
collected in a representative sample, caution is needed in generalisation
of the results to other populations. Another important limitation of the study
is that we did not have any information on the characteristics of the physi-
cians who prescribed benzodiazepines to the respondents. Indeed, since
benzodiazepines as a rule can only be obtained by prescription, informa-
tion on the prescribing physicians might improve the goodness of fit of the
multivariate model for benzodiazepine use.
A highly significant discrepancy was found between Aalst and Liège
for the consumption of benzodiazepines in general. It is not clear from
these data whether patterns of benzodiazepine consumption in Liège
differed from those in Aalst, because no information was available on the
duration, frequency or dose of benzodiazepine use. In the survey of
Pestiaux et al (2) in adult members of the socialist health insurance
agency, a significantly higher tranquillizer consumption was found in
Wallonia compared to Flanders for daily use, but not for use in general
(daily or intermittent use). 
The existing regional differences on sociodemographic variables (e.g.
the degree of urbanisation), health-related behaviours and attitudes could
Model without morbidity Model with morbidity 
variables variables
Variable OR 95% CI OR 95% CI
Physical disorders (compared to none)
one 1.55 1.17-2.06
two 1.49 1.10-2.00
three or more 1.82 1.35-2.47
Mental disorders (compared to none) 4.44 3.16-6.25
Central Nervous System disorders 1.19 0.91-1.54
(compared to none)
-2*loglikelihood (chi-square) 4060.190 3520.286
Legend: The reference category for each variable is cited between brackets. Age is included as a linear variable in the
analysis. OR= odds ratio; CI= confidence interval; P=percentile.
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not explain the higher prevalence of benzodiazepine use in Liège. The
odds ratio for the variable ‘region’ was still 1.45 after controlling for these
variables (unadjusted odds ratio 1.54). However, when taking into
account morbidity information the odds ratio dropped to 1.00. 
Although detailed information was retrieved on the respondents’
morbidity, its value is limited since it was based on self-reported data and
the different measures showed some inconsistencies. It would be inter-
esting to know to what degree the higher level of self-reported morbid-
ity in Liège compared to Aalst relates to other health parameters, such
as the formal diagnosis of a physician. However, no such information
was available.
A simple conclusion could be that the regional differences in benzo-
diazepine use are completely justifiable because of differences in
morbidity. Is this a correct analysis? Or, are both benzodiazepine
prescriptions and reported psychosocial morbidity exponents of a differ-
ence in “culture” between the two regions? One hypothesis could be that
the cultural acceptance of disease as a legitimation for social dysfunc-
tion (e.g. being unemployed not going to work because of distress) is
different in both regions, with more complaints (more “morbidity”) and
more benzodiazepine use in Liège than in Aalst. 
In order to understand the complexity of the phenomenon we hypo-
thesise a conceptual framework. Figure 1 illustrates that social determi-
nants may influence the physician, benzodiazepine prescription, the
patient and morbidity-labelling. Moreover it illustrates the interaction
between “morbidity” and “social determinants” as morbidity may con-
tribute to a downward social mobility.
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It is clear that the label “depression” will show up quicker when you
are visiting a single mother, unemployed, with 2 hyperkinetic children
living at the 14th floor in a social apartment, than when you visit a
woman, living in a green area, with an interesting job, a nice husband
and two brilliant children. So social conditions may “influence” diagnos-
tic labelling. Lamberts (22) defines the “labelling” of a certain condition
as a “disease” as one of the five characteristics of “family medicine” and
emphasises the importance of “norms” and “values” for the labelling
process. The figure also makes clear that prescription of benzodi-
azepines may have a “tranquillizing” effect on the consequences of
social conditions (benzodiazepines tranquillise the symptoms and
morbidity that are related to the social determinants and personal
characteristics). From a societal perspective it could be very “adequate”
that general practitioners in Liège prescribe more tranquillisers, taking
into account the stressful social living conditions. So in a complex ana-
lysis all interactions should be carefully examined and the “effect” that
regional differences disappear through introduction of morbidity, may
obscure social inequities.
Conclusion
Differences in benzodiazepine use between Liège and Aalst are partly
explained by differences in self-reported morbidity. Objective morbidity
data and information on prescribers might give more insight in such
regional differences.
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